Maven Clinic Expands Direct-to-Consumer Platform Nationwide

Event summary

  • Maven Clinic launches direct-to-consumer platform, opening beta waitlist on March 11, 2026.
  • Platform offers integrated virtual care across 30+ specialties, GLP-1 care, and hormone care.
  • Company has partnered with 2,300 employers and health plans, covering 28 million lives globally.
  • Enterprise clients can add consumer offerings for members starting in 2027.
  • Maven has raised $425 million from investors including General Catalyst and Sequoia.

The big picture

Maven Clinic's expansion into direct-to-consumer care comes as women's health becomes a more fragmented yet lucrative market. The company leverages a decade of clinical experience and employer partnerships to offer a unified platform, addressing gaps in care coordination. This move positions Maven to capitalize on growing demand for personalized, integrated healthcare solutions.

What we're watching

Market Penetration
Whether Maven can successfully transition from B2B to B2C while maintaining enterprise partnerships.
Competitive Positioning
How Maven's integrated approach will differentiate it in the crowded women's health market.
Regulatory Compliance
The pace at which regulatory frameworks adapt to direct-to-consumer hormone and GLP-1 care models.

Related topics

Expansion